NEW YORK (GenomeWeb) — Researchers from several European institutions working with AstraZeneca have published a study demonstrating that measuring EGFR mutations from circulating tumor DNA compares favorably to tissue-based EGFR mutation status.
The results, published in the September issue of theJournal of Thoracic Oncology, suggest that in cases where tissue biopsies are not possible, clinicians should potentially consider using blood-based EGFR testing to guide care.